Back to search results

EASi-KIDNEY™ Study for Chronic Kidney Disease

This study is looking for adults with chronic kidney disease (CKD) who are at risk of their kidney disease getting worse. You can join if you have CKD, whether or not you have type 2 diabetes, and regardless of other kidney medications you might be taking. The study aims to see if a medicine called BI 690517, when taken with empagliflozin, can help protect your heart and kidneys. Success in this study means preventing kidney disease from getting worse, avoiding hospitalization for heart failure, or preventing cardiovascular death. The study plans to enroll 11,000 people, but its current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 11,000 participants. It involves testing BI 690517, a placebo, and empagliflozin.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 4 years to track kidney disease progression, heart failure hospitalizations, or cardiovascular death.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06531824

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Recruiting
PHASE3Ages 18+InterventionalTreatment
Boehringer Ingelheim
~11,000 participants
Updated 2026-09-17 on ClinicalTrials.gov
What's tested:BI 690517Placebo matching BI 690517Empagliflozin

At a glance

Recruiting sites
557 of 557 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.
Measured over up to 4 years

Conditions

Kidney Disease, Chronic

Explore related trials

Chronic Kidney Disease

NCT06531824

Where you'd take part

This study runs at 557 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • 168 Parklands Medical Centre

    Weston-super-Mare, United Kingdomstudy coordinator listed

    Recruiting

  • A. O. Universitaria Careggi

    Florence, Italystudy coordinator listed

    Recruiting

  • A.S.O. S. Croce e Carle

    Cuneo, Italystudy coordinator listed

    Recruiting

  • Aakash Healthcare Super Speciality Hospital

    Dwārka, Indiastudy coordinator listed

    Recruiting

  • Aalborg Universitetsshospital

    Aalborg, Denmarkstudy coordinator listed

    Recruiting

  • Academy Of Diabetes, Thyroid And Endocrine, PA

    El Paso, Texasstudy coordinator listed

    Recruiting

  • Accord Superspeciality Hospital

    Faridabad, Indiastudy coordinator listed

    Recruiting

  • Advanced Heart Care, LLC

    Bridgewater, New Jerseystudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Boehringer Ingelheim
[email protected]
1-800-243-0127
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Evidence of chronic kidney disease (CKD) at risk of kidney disease progression is defined on the basis of local laboratory results recorded at least 3 months before and at the time of the Screening visit, and requires:
Neither requires an Aldosterone Synthase inhibitor (ASi) or Mineralocorticoid Receptor Antagonist (MRA), nor that such treatment is definitely inappropriate.

Exclusion

Blood potassium of \>5.2 mmol/L at screening visit
Blood Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \>3x Upper Limit of Normal (ULN) at Screening visit (only one is required, with ALT preferred)
Known liver cirrhosis
On dialysis, functioning kidney transplant, or scheduled living donor transplant
Treated with new immunosuppression therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days
Receiving more than one Renin-Angiotensin System (RAS) inhibitor (i.e. on dual therapy with two of an Angiotensin-Converting Enzyme inhibitor (ACEi), Angiotensin Receptor Blocker (ARB) or direct renin inhibitor)
Currently treated with an Mineralocorticoid Receptor Antagonist (MRA) (e.g. spironolactone, eplerenone, finerenone)

What this trial measures

  • Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.up to 4 years

    Kidney disease progression is defined as kidney failure or a sustained decline of ≥40% in estimated Glomerular Filtration Rate (eGFR) from randomization